StockNews.AI
FGEN
StockNews.AI
169 days

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

1. FibroGen to announce Q4 and 2024 financial results on March 17. 2. Management will host a call for detailed corporate and financial updates. 3. Roxadustat is approved in numerous countries for anemia treatment. 4. FibroGen evaluates roxadustat for lower-risk myelodysplastic syndrome in the U.S. 5. Development continues for FG-3246 targeting prostate cancer and related biomarkers.

Earnings
-5.33%Current Return
VS
-1.18%S&P 500
$0.380703/03 05:42 PM EDTEvent Start
$0.360403/05 12:20 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results and product developments may reassure investors. Historical results announcements often influence stock prices positively.

How important is it?

The announcement of financial results and product developments are crucial for investor sentiment.

Why Short Term?

Q4 results and call will soon reveal key financial insights affecting immediate stock performance.

Related Companies

CKDEVRNFSUG
March 03, 2025 16:45 ET  | Source: FibroGen, Inc. SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website. About FibroGen  FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com. For Investor Inquiries:David DeLucia, CFASenior Vice President and Chief Financial Officerir@fibrogen.com   

Related News